Momelotinib (Omjjara, GSK) is indicated for 'the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.'
The dosage schedule is available in the summary of product characteristics for momelotinib.
The list price of momelotinib is £5,650 for a 30‑tablet pack of 100 mg, 150 mg or 200 mg tablets (excluding VAT; company submission).
The company has a commercial arrangement. This makes momelotinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.